Phenylethylaminergic mechanisms in attention-deficit disorder

doi:10.1016/0006-3223(91)90207-3

Biological Psychiatry

Volume 29, Issue 1, 1 January 1991, Pages 15-22

https://doi.org/10.1016/0006-3223(91)90207-3 Get rights and content

Abstract

Urinary excretion (24-hr) of β-phenylethylamine (PEA), phenylacetic acid (PAA), phenylalanine (Phe), and p-tyrosine (Tyr), and plasma levels of PAA, Phe, and Tyr were examined in 18 normal children and 26 children diagnosed as having attention-deficit hyperactivity disorder (ADHD). The results indicated that urinary excretion (expressed per g of creatinine) of free and total PEA was significantly lower in the ADHD patients, and plasma levels of Phe and Tyr were also decreased in the ADHD subjects compared with the normal controls.

References (46)

G.B. Baker et al.
Electron-capture gas chromatographic analysis of β-phenylethylamine in tissues and body fluids using pentafluorobenzenesulfonyl chloride for derivatization
J Chromatogr Biomed Appl
(1986)
B.A. Davis
Biogenic amines and their metabolites in body fluids of normal, psychiatric and neurological subjects
J Chromatogr
(1989)
L.E. DeLisi et al.
Phenylethylamine excretion in depression
Psychiatry Res
(1984)
T. Eriksson et al.
β-adrenergic control of brain uptake of large neutral amino acids
Life Sci
(1988)
N.J. Fuller et al.
Factors influencing the production of creatinine: Implications for the determination and interpretation of urinary creatine and creatinine in man
Clin Chim Acta
(1988)
D.A. Jenner et al.
24-h catecholamine excretion: Relationships with age and weight
Clin Chim Acta
(1987)
J.F. Leckman et al.
Effects of oral clonidine on plasma 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG) in man: Preliminary report
Life Sci
(1980)
M. Raiteri et al.
Effects of sympathomimetic amines on the synaptosomal transport of noradrenaline, dopamine and 5-hydroxytryptamine
Eur J Pharmacol
(1977)
G.A. Rogeness et al.
Attention deficit disorder symptoms and urine catecholamines
Psychiatry Res
(1989)
H.V. Szymanski et al.
Plasma phenylethylamine and phenylalanine in chronic schizophrenic patients
Biol Psychiatry
(1987)

J.T.F. Wong et al.

Rapid and simple procedure for the determination of urinary phenylacetic acid using derivatization in aqueous medium followed by electron-capture gas chromatography

J Chromatogr Biomed Appl

(1988)

D.R. Wood et al.

Treatment of attention deficit disorder with dl-phenylalanine

Psychiatry Res

(1985)

J.M. Yeung et al.

A simple automated gas chromatographic analysis of amino acids and its application to brain tissue and urine

J Chromatogr Biomed Appl

(1986)

S. Yoshimoto et al.

Urinary trace amine excretion and platelet monoamine oxidase activity in schizophrenia

Psychiatry Res

(1987)

A.J. Zametkin et al.

Phenylethylamine excretion in attention deficit disorder

J Am Acad Child Psychiatry

(1984)

G.B. Baker et al.

Urinary increase of β-phenylethylamine and phenylacetic acid in volunteer subjects treated with phenelzine

J Neurochem

(1989)

R.A. Bornstein et al.

Neuropsychological correlates of urinary amine metabolites in Tourette's syndrome

Int J Neurosci

(1988)

R.A. Bornstein et al.

Phenylethylamine metabolism in Tourette's syndrome

J Neuropsychiatry Clin Neurosci

(1990)

A.A. Boulton

Trace amines and the neurosciences: An overview

A.A. Boulton et al.

Separation, determination and quantitative analysis of urinary phenylethylamine

J Chromatogr

(1971)

G. Cassens et al.

Alterations in brain norepinephrine metabolism induced by environmental stimuli previously paired with inescapable shock

Science

(1980)

C.K. Conners

Symptom patterns in hyperkinetic, neurotic, and normal children

Child Dev

(1970)

E. Fischer et al.

β-phenylethylamine in human urine

Arzneim-Forsch

(1968)

Cited by (57)

Trace amine-associated receptor 1 modulates motor hyperactivity, cognition, and anxiety-like behavior in an animal model of ADHD
2022, Progress in Neuro-Psychopharmacology and Biological Psychiatry
Trace amine-associated receptor 1 (TAAR1) is a G protein-coupled receptor that has recently been implicated in several psychiatric conditions related to monoaminergic dysfunction, such as schizophrenia, substance use disorders, and mood disorders. Although attention-deficit/hyperactivity disorder (ADHD) is also related to changes in monoaminergic neurotransmission, studies that assess whether TAAR1 participates in the neurobiology of ADHD are lacking. We hypothesized that TAAR1 plays an important role in ADHD and might represent a potential therapeutic target. Here, we investigate if TAAR1 modulates behavioral phenotypes in Spontaneously Hypertensive Rats (SHR), the most validated animal model of ADHD, and Wistar Kyoto rats (WKY, used as a control strain). Our results showed that TAAR1 is downregulated in ADHD-related brain regions in SHR compared with WKY. While intracerebroventricular (i.c.v.) administration of the selective TAAR1 antagonist EPPTB impaired cognitive performance in SHR, i.c.v. administration of highly selective TAAR1 full agonist RO5256390 decreased motor hyperactivity, novelty-induced locomotion, and induced an anxiolytic-like behavior. Overall, our findings show that changes in TAAR1 levels/activity underlie behavior in SHR, suggesting that TAAR1 plays a role in the neurobiology of ADHD. Although additional confirmatory studies are required, TAAR1 might be a potential pharmacological target for individuals with this disorder.
Photodelivery of β-phenylethylamines
2020, Organic and Biomolecular Chemistry
A proton transfer compound template phenylethylamine: Synthesis, a collective experimental and theoretical investigations
2019, Journal of Molecular Structure
Citation Excerpt :
PEA) levels are shown to be very low in the biological fluids of depressed patients. Biochemically, PEA plays the role of an excitatory neurotransmitter and organizes neuronal potentials to promote glutamate activity and trigger neurotransmitters [6–8]. As part of our current study, we report our investigations on a new organic-inorganic hybrid compound: Phenylethylammonium nitrate with general chemical formula (C6H5(CH2)2NH3)NO3 (PEAN).
Synthesis, crystalline architecture, vibrational spectroscopy, thermal analysis, electrical behavior and detailed theoretical DFT studies has been reported for the new inorganic-organic hybrid material phenylethylammonium trioxonitrate with general chemical formula (C₆H₅(CH₂)₂NH₃)NO₃ (PEAN). The determination of crystal structures plays a significant to understanding weak, intra and intermolecular, interactions that great influence crystal packing. PEAN has been crystallized to the monoclinic system with space group P2₁/c and the network parameters obtained are a = 5.9497(8) Å, b = 20. 494(3) Å, c = 8.4528(11) Å, β = 113. 812(8)°, V = 942.9(2) Å³ and Z = 4. The atomic arrangement of the PEAN compound can be described by 3D framework. The organic cations are linked to the nitrate anions by means of an assortment of NH⋯O hydrogen bonding trapped in layers at y = ¼ and ¾. These layers are interrelated via CH⋯π interactions involving organic cations, an infinite chain are consequently created along the c-axis. Hirshfeld surfaces and 2D fingerprint plots estimate the weak intermolecular interactions accountable for the generation of crystal packing. The structural propriety and vibrational spectral analyze of PEAN have been investigated by using DFT calculations at B3LYP/6-311++G(d,p) level of theory. Intermolecular interactions were studied by NBO and AIM analyses. Thermal analysis (TG-DTA and DSC) and dielectric conductivity was also investigated. These measurements were realized to discuss the observed phase transition mechanism in the vicinity of 340 K.
The emerging roles of human trace amines and human trace amine-associated receptors (hTAARs) in central nervous system
2016, Biomedicine and Pharmacotherapy
Citation Excerpt :
This novel discovery will improve the confidence of the diagnostic efforts, possibly leading to reduced misdiagnosis and overmedication. Specifically, the urinary output of PEA was lower in a population of children suffering from ADHD, as compared to the healthy control population, an observation that was paralleled by reduced PEA levels in ADHD individuals [37,38]. Methylphenidate (MPD) is a central nervous system (CNS) stimulant, which belongs to the phenethylamine group and is mainly used in the treatment of attention deficit hyperactive disorder (ADHD).
Human trace amines (TAs) are endogenous compounds, previously almost ignored in human pathology for many reasons (difficulty of their measurement in biological fluids, unknown receptors for elusive amines), are now considered to play a significant role in synaptic transmission within the central nervous system (CNS) acting as neuromodulators. The recent discovery of a novel family of G-protein-coupled receptors (GPCRs) that includes individual members that are highly specific for TAs indicates a potential role for TAs as vertebrate neurotransmitters or neuromodulators, although the majority of these GPCRs so far have not been demonstrated to be activated by TAs. Human trace amine receptors (including TAAR1 TAAR2 TAAR5 TAAR6 TAAR8 TAAR9) are expressed in the brain and play significant physiological and neuropathological roles by activation of trace amines. We herein discuss the recent findings that provide insights into the functional roles of human trace amines (including P-Octopamine, β phenylethylamine, Tryptamine, Tyramine, Synephrine, 3-Iodothyronamine, 3-Methoxytyramine, N-Methyltyramine, N-Methylphenethylamine) in brain. Furthermore, we discuss the known functions of human trace amine receptors in brain.
Trace Amines and Their Relevance to Neurological Disorders: A Commentary
2016, Trace Amines and Neurological Disorders: Potential Mechanisms and Risk Factors
Trace amines are structurally and metabolically related to classical monoamine neurotransmitters (dopamine, norepinephrine, and serotonin) in the mammalian brain. Under physiological conditions, trace amines are found at low concentrations and modulate several physiological processes including aminergic neurotransmission. However, they are present at abnormal levels in many brain diseases, implicating their importance in the pathology of several brain diseases. Trace amines exert their effect by activating a class of G-protein-coupled receptors, so-called trace amine-associated receptors (TAARs). TAAR1 is a protein that is expressed in several mammalian brain areas, and can be activated by endogenous trace amines as well as by dopaminergic, adrenergic, and serotonergic ligands. In vivo studies have shown an inhibitory influence of TAAR1 on dopamine neurotransmission, controlling cognition including movement, suggesting the therapeutic potential of TAAR1. This commentary focuses on the possible link among monoaminergic neurotransmitters, trace amines, and neurological disorders, having a common symptom of depression.
Trace Amines in Neuropsychiatric Disorders
2016, Trace Amines and Neurological Disorders: Potential Mechanisms and Risk Factors
Trace amines (TAs) are biogenic amines located in mammalian brains and peripheral nervous tissues in low concentrations. Examples of TAs include phenylethylamine, tyramine, tryptamine, and octopamine, all of which are closely related to dopamine, norepinephrine, and serotonin neurotransmitter systems metabolically. Understanding the role of TAs in the progression of neuropsychiatric disorders is important for elucidating the pathway(s) and mechanism(s) leading up to the management of such disorders. Recently, TAs have been implicated in various neuropsychiatric disorders such as, depression, schizophrenia, attention deficit hyperactivity disorder, Parkinson disease, Alzheimer disease, Reye syndrome, Tourette syndrome, epilepsy, and migraines. The neuropsychiatric disorders and the associated psychotropic drugs, coupled with the possibility of the elucidation of the newer pathways have been explored in this chapter along with highlighting the recent advances in the area of TAs chemistry and synaptic physiology and their interrelationships.

View all citing articles on Scopus

View full text

Phenylethylaminergic mechanisms in attention-deficit disorder

Abstract

J Chromatogr Biomed Appl

J Chromatogr

Psychiatry Res

Life Sci

Clin Chim Acta

Clin Chim Acta

Life Sci

Eur J Pharmacol

Psychiatry Res

Biol Psychiatry

J Chromatogr Biomed Appl

Psychiatry Res

J Chromatogr Biomed Appl

Psychiatry Res

J Am Acad Child Psychiatry

Urinary increase of β-phenylethylamine and phenylacetic acid in volunteer subjects treated with phenelzine

J Neurochem

Neuropsychological correlates of urinary amine metabolites in Tourette's syndrome

Int J Neurosci

Phenylethylamine metabolism in Tourette's syndrome

J Neuropsychiatry Clin Neurosci

Trace amines and the neurosciences: An overview

Separation, determination and quantitative analysis of urinary phenylethylamine

J Chromatogr

Alterations in brain norepinephrine metabolism induced by environmental stimuli previously paired with inescapable shock

Science

Symptom patterns in hyperkinetic, neurotic, and normal children

Child Dev

β-phenylethylamine in human urine

Arzneim-Forsch